Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
6.56
-0.25 (-3.67%)
At close: Mar 20, 2026, 4:00 PM EDT
6.57
+0.01 (0.15%)
After-hours: Mar 20, 2026, 4:10 PM EDT
Company Description
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Kalaris Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Andrew Oxtoby |
Contact Details
Address: 400 Connell Drive, Suite 5500 Berkeley Heights, New Jersey 07922 United States | |
| Phone | 650-249-2727 |
| Website | kalaristx.com |
Stock Details
| Ticker Symbol | KLRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 482929106 |
| ISIN Number | US4829291065 |
| Employer ID | 83-1971007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Oxtoby | President, Chief Executive Officer and Director |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director and Co-Founder |
| Dr. Michael Philip Dybbs Ph.D. | Director and Co-Founder |
| Dr. Napoleone Ferrara M.D. | Independent Director and Co-Founder |
| Matthew Gall M.B.A. | Chief Financial Officer and Treasurer |
| Brett R. Hagen | Chief Accounting Officer |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |
| Kristine Curtiss | Senior Vice President of Clinical |
| Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2026 | 144 | Filing |
| Mar 17, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13D/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Dec 22, 2025 | SCHEDULE 13D/A | Filing |
| Dec 18, 2025 | 8-K | Current Report |
| Dec 17, 2025 | 8-K | Current Report |